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OBJECTIVES The study served to present the in-hospital and six-month clinical outcome and also the
long-term survival data of a consecutive series of patients undergoing stenting for unprotected
left main coronary artery (LMCA) disease.
BACKGROUND Revascularization with coronary bypass surgery has been generally recommended for
treatment of left main coronary stenosis. Improvements in angioplasty and coronary stent
techniques and equipment may result in the wider applicability of a percutaneous approach.
METHODS A total of 92 consecutive patients underwent unprotected LMCA stenting between March
1994 and December 1998. For the initial 39 patients (group I) angioplasty was performed
only when surgical revascularization was contraindicated. The remaining 53 patients (group
II) also included patients in whom surgery was feasible. Patients were followed for 7.3 6 5.8
months (median 239 days; range 49 to 1,477 days).
RESULTS Compared to group I, group II patients had higher left ventricular ejection fraction (60 6
12% vs. 51 6 16%, p , 0.01), less severe LMCA stenosis (68 6 12% vs. 80 6 10%, p ,
0.001), lower surgical risk score (13 6 7 vs. 20 6 7, p , 0.001), and had angioplasty more
often performed via the radial approach (88% vs. 23%, p , 0.001) with smaller guiding
catheters (6F: 49% vs. 15%; 8F: 2% vs. 77%, p , 0.001). The procedural success rate was
100%. In-hospital mortality was 4% (4 deaths, 3 cardiac). During follow-up there were six
deaths, 13 patients required repeat percutaneous transluminal coronary angioplasty (4
LMCA), and two required coronary artery bypass graft surgery. Estimated survival (6SEE)
was 89 6 6.3% at 500 days and 85 6 12% at 1,000 days post-stenting. Overall mortality was
3.8% in group II and 20.5% in group I (p , 0.02).
CONCLUSIONS Coronary stenting can be performed safely in high-risk individuals with acceptable
intermediate-term outcome. It may be feasible to broaden the application of this technique
in selected patients needing revascularization for left main coronary disease. (J Am Coll
Cardiol 2001;37:832–8) © 2001 by the American College of Cardiology
Left main coronary artery (LMCA) disease is found in 3%
to 5% of patients undergoing cardiac catheterization (1,2)
for ischemic chest pain, congestive heart failure (CHF) or
cardiogenic shock. Whereas medical therapy of patients
with LMCA disease is associated with a poor prognosis
(3–5), revascularization by coronary artery bypass grafting
(CABG) has been shown to improve survival (6–12) and is
generally the preferred therapeutic option.
Early studies reporting the results of balloon angioplasty
for unprotected LMCA stenosis have shown poor long-
term results (13–15). However, adjunctive LMCA stenting
has more recently been proposed for selected patients with
prohibitive surgical risk (16–22).
Current techniques of stent deployment using high bal-
loon pressures with or without ultrasound guidance together
with the combined use of platelet adenosine diphosphate
receptor antagonists and aspirin have been associated with a
dramatic reduction in the risk of subacute stent thrombosis
(23–26). This study evaluated our experience to date with
LMCA stenting and compared the outcome in two consec-
utive patient groups: an initial group who were judged
unsuitable candidates for CABG surgery, and a more recent
group that also included patients without absolute contra-
indications for CABG surgery who had coronary anatomy
that appeared suitable for percutaneous transluminal coro-
nary angioplasty (PTCA).
METHODS
Study Patients
Between March 1994 and December 1998, out of a total of
6,006 interventional coronary procedures performed at
Clinique Pasteur, 92 patients underwent balloon angioplasty
and stent implantation for significant unprotected (i.e.,
without functioning bypass grafts to branches of the left
coronary artery) LMCA stenosis. Before PTCA, the poten-
tial risk of CABG surgery was evaluated for each patient by
considering the patient’s age, the presence of diabetes
mellitus, chronic obstructive pulmonary disease, peripheral
vascular disease, cardiogenic shock, prior heart surgery, or
poor ventricular function and the possibility of incomplete
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and/or emergent revascularization. The Parsonnet surgical
risk score (27) was calculated for each patient. All patients
treated until October 1996 were judged to be unsuitable
candidates for CABG surgery (group I, n 5 39) by our
institution’s cardiothoracic surgeons in consultation with
the patient’s attending cardiologist, because of unacceptable
operative risk considering the factors outlined above. After
we reviewed the results of this initial cohort, we decided to
broaden the selection criteria to include some patients who
were otherwise reasonable candidates for surgery (group II,
n 5 53).
During the latter period, angioplasty was avoided in
patients with bifurcation LMCA stenoses or heavily calci-
fied lesions when CABG surgery was possible.
Stent Implantation Procedure
All patients except those presenting with acute myocardial
infarction (MI) were pretreated with aspirin (250 mg/day)
and ticlopidine (500 mg/day) for at least 72 h. Intravenous
(IV) heparin 100 U/kg was administered at the commence-
ment of the procedure, with further bolus doses to maintain
the activated clotting time at above 200 s. All patients had
neuroleptanalgesia administered by a cardiac anesthesiolo-
gist. Endotracheal intubation was required in two patients
with cardiogenic shock, and intraaortic balloon counterpul-
sation was used in two patients. Systolic blood pressure was
maintained at above 110 mm Hg using pressor agents if
needed.
Arterial access was obtained via a transfemoral (using 7F
or 8F guiding catheters in 37 patients, 40%) or transradial
approach (using 6F or 7F guiding catheters in 55 patients,
60%). Predilation was performed with short (,40 s) and
repeated balloon inflations in order to limit the duration of
myocardial ischemia. In all cases, an inflation pressure of
.15 atmospheres (atm) was used to obtain a satisfactory
lumen in order to facilitate stent placement. Plaque debulk-
ing using a Rotablator™ device (Boston Scientific, Maple
Grove, Minnesota) was used in seven patients with heavily
calcified plaques to facilitate balloon expansion and stent
deployment. Perfusion balloon catheters were not used
during predilation or during stent implantation. Stent de-
ployment was performed using high pressures (.15 atm)
with a rapid-exchange, semicompliant balloon catheter.
Tubular design stents were selected for ostial and mid-
LMCA stenoses. Coil design stents were used for distal
LMCA stenoses that involved the bifurcation into the left
anterior descending coronary artery and left circumflex
coronary artery.
Patients undergoing transfemoral catheterization had the
arterial sheath either removed immediately with hemostasis
achieved by the Perclose (Perclose, Menlo Park, California)
or Angioseal (Sherwood Medical/Quinton Instrument,
Bothell, Washington) device, or after 6 h, using the Femo-
stop device (Radi Medical Systems AB, Uppsala, Sweden).
The sheath was always removed immediately when the
transradial approach was used. All patients were monitored
in the intensive care unit for the first 24 h after the
procedure.
Angiographic Analysis
Minimum lumen diameter (MLD) and vessel reference
diameter were measured using an on-line quantitative cor-
onary angiography system (DCI/ACA, Phillips, the Neth-
erlands). Intracoronary nitrates were injected before each
angiographic assessment. The diameters of normal seg-
ments proximal and distal to the treated area were averaged
to determine the reference diameter, except for ostial or
bifurcation lesions where the adjacent normal segment was
used. Lesions were considered significant if the percentage
diameter stenosis was .50%.
Definitions
Angiographic success was defined as a reduction in percent
diameter stenosis to ,30%. Procedural success required, in
addition to angiographic success, the absence of any major
cardiac events as defined in the following text during the
period of hospitalization. Major cardiac events included
recurrent angina requiring repeat catheterization, Q- or
non-Q-wave myocardial infarction (MI), the need for
urgent or semiurgent bypass surgery, and death. Myocardial
infarction was defined clinically as the occurrence of symp-
toms or typical electrocardiographic changes following the
stent procedure. Cardiac enzymes were not measured rou-
tinely unless there was clinical suspicion of an ischemic
event.
Follow-up
Follow-up status, including death (cardiac or noncardiac),
reported MI and need for repeat revascularization, was
obtained for all patients at approximately six months after
the PTCA procedure. Symptomatic status was not deter-
mined and not considered helpful in this group of patients
with a high prevalence of multisite dilation. Long-term
survival data were obtained in all patients from clinic visits
or telephone interview with the patient’s physician.
Statistical Analysis
Clinical and angiographic data on all patients were prospec-
tively recorded on standard forms and stored in a comput-
erized information system (AS/400, IBM). Continuous data
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft
CHF 5 congestive heart failure
LMCA 5 left main coronary artery
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
MLD 5 minimum lumen diameter
PTCA 5 percutaneous transluminal coronary
angioplasty
RCA 5 right coronary artery
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are reported as mean 6 SD and were compared using the
Student t test, except for percentage diameter stenosis
following stenting, which is expressed as mean (range) and
was compared using the Mann-Whitney U test. Survival
was calculated by the Kaplan-Meier method and expressed
in the text as percentage 6 SE. A comparison of overall
survival between groups I and II was attempted using the
log-rank test; however, follow-up duration was markedly
shorter in group II with few events, and the data are not
presented. Categorical variables were compared using chi-
square analysis or the Fisher exact test where appropriate. A
multivariate model of predictors of adverse outcome did not
have sufficient power to discriminate the small number of
events, and the data are not presented. A p value of ,0.05
was considered significant.
RESULTS
Patient Characteristics
The baseline clinical characteristics of the 92 patients are
shown in Table 1. Seventy-four patients were men, with a
mean age of 74 years (range 47 to 90 years). Most patients
presented with unstable angina and four underwent stent
implantation during the acute phase of MI. The average
Parsonnet score was 15 6 6.9 (range, 0 to 27). The baseline
angiographic and procedural details are displayed in
Table 1.
Table 2 outlines the differences between group I and
group II. Patients of group I had a higher Parsonnet score
(20 6 7 vs. 14 6 8, p , 0.001), lower left ventricular
ejection fraction (LVEF) (51 6 16 vs. 60 6 12, p , 0.01),
more severe LMCA stenoses (80 6 10% vs. 68 6 12%, p ,
0.001), more bifurcation stenoses (15% vs. 0%, p , 0.005)
and angioplasty more often performed via the femoral
approach (77% vs. 12%, p , 0.001) with the use of larger
guiding catheter (8F guiding catheter: 77% vs. 2%; 6F: 15%
vs. 49%; p , 0.001). Eighty-eight percent of group II
patients had LMCA stent implantation performed via the
transradial approach. This reflects a progressive trend at our
institution where a transradial approach is currently at-
tempted in all elective PTCA cases.
In-Hospital Outcome
Sixty-three patients underwent multisite dilation, including
13 who underwent dilation of the right coronary artery at
the time of the LMCA dilation. Two patients received two
stents (GRII 1 Palmaz-Schatz stent in 1; two Palmaz-
Schatz stents in 1) (Table 3). Angiographic success was
achieved in all patients, and the mean final stent diameter
was 3.9 6 0.51 mm. In-hospital major adverse cardiac
events included four procedure-related deaths (4%): two
from ventricular arrhythmias, one from heart failure, and
one from gastrointestinal bleeding (Table 4). No MI was
Table 1. Baseline Clinical and Angiographic Characteristics
Characteristics n 5 92 (%)
Age (yrs) 74.3 6 8.1
Male gender 74 (80)
Hypertension 41 (45)
Diabetes mellitus 20 (22)
Hypercholesterolemia 26 (28)
Smoker 37 (40)
Unstable angina 58 (63)
Recent MI 7 (8)
Acute MI 4 (4)
Parsonnet score 15 6 6.9
LVEF (%) 56.1 6 14.7
Three-vessel disease 66 (72)
RCA stenosis 45 (49)
Mean LMCA stenosis (%) 72.8 6 13.0
LMCA 5 left main coronary artery; LVEF 5 left ventricular ejection fraction; MI 5
myocardial infarction; RCA 5 right coronary artery.
Table 2. Baseline Clinical, Angiographic and
Procedural Characteristics
Characteristics
Group I
(n 5 39)
Group II
(n 5 53)
p
Value
Age (yrs) 75 6 9 74 6 8 NS
Male gender (%) 82 79 NS
Unstable angina (%) 77 62 , 0.1
Parsonnet score 20 6 7 13 6 7 , 0.001
LVEF (%) 51 6 16 60 6 12 , 0.01
RCA stenosis (%) 67 63 NS
Mean LMCA stenosis (%) 80 6 10% 68 6 12% , 0.001
Bifurcation stenosis (%) 15 0 , 0.005
Arterial access
Femoral 79% 12%
Radial 21% 88% , 0.001
Guide catheter size
8F 77% 2%
7F 8% 49%
6F 15% 49% , 0.001
LMCA 5 left main coronary artery; LVEF 5 left ventricular ejection fraction;
RCA 5 right coronary artery.
Table 3. Summary of Procedures
Procedures Patients (%)
Target Vessel
LMCA alone 29 32
LMCA 1 LAD 21 23
LMCA 1 LCX 15 26
LMCA 1 LAD 1 LCX 14 15
LMCA 1 RCA 7 8
LMCA 1 LAD 1 RCA 5 5
LMCA 1 LAD 1 LCX 1 RCA 1 1
Stents utilized
Gianturco-Roubin GRII (Cook) (GR)* 26 28
GFX (AVE) 21 22
Palmaz-Schatz (Johnson & Johnson) (PS)* 16 17
Cross-Flex (Cordis) 15 16
Nir (Scimed, Boston Scientific) 6 6
Enforcer (Cardio-Vascular Dynamics) 4 4
Multilink (Advanced Cardiovascular Systems) 3 3
Wiktor (Bard) 2 2
XT (Bard) 1 1
Total 94
*PS 3 2: 1 patient received 2 Palmaz-Schatz stents; PS 1 GR: 1 patient received 1
Palmaz-Schatz and 1 Gianturco-Roubin stent.
LAD 5 left anterior descending coronary artery; LCX 5 left circumflex coronary
artery; LMCA 5 left main coronary artery; RCA 5 right coronary artery.
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observed. No patients needed emergency bypass surgery; no
patients had recurrent angina during hospitalization.
Follow-Up
During follow-up (7.3 6 5.8 months; median 239 days;
range 49 to 1,477 days), there were six additional deaths
(7%): one sudden death was presumed cardiac; one was due
to ventricular arrhythmia; three patients died of CHF, and
there was one noncardiac death from pulmonary cancer (this
patient had been referred for LMCA stenting because of
limited life expectancy). The Kaplan-Meier survival esti-
mates depicted in Figure 1 show 500- and 1,000-day
survival estimates of 89 6 6.3% and 85 6 12%, respectively.
Of the 82 (89%) patients surviving at six months, four had
symptomatic LMCA restenosis at three, four, five and six
months, respectively, and were treated by repeat balloon
angioplasty within the stent. Nine other patients had repeat
PTCA to other vessels, and two patients had bypass surgery
for restenosis (1 LMCA; 1 LAD).
Overall mortality data are summarized in Table 4. Total
Figure 1. Kaplan-Meier survival curve.
Table 4. In-Hospital and Six-Month Complications
Complications
Overall
(n 5 92)
Group I
(n 5 39)
Group II
(n 5 53)
p Value
Group I vs.
Group II
In-hospital outcome
Non-Q-wave MI 0 0 0
Q-wave MI 0 0 0
Repeat PTCA 0 0 0
CABG 0 0 0
Death 4 (4.3%) 3 (7.6%) 1 (1.8%) NS
Noncardiac 1 1 0
Cardiac 3 2 1
VF/arrhythmia 1 1
Sudden death 0 0
CHF 1 0
Follow-up (n 5 88) (n 5 36) (n 5 52)
Non-fatal MI 0 0 0
Re-PTCA
LMCA
4 1 3
Re-PTCA (other) 9 5 4
CABG 2 1 1
Death 6 (6.8%) 5 (13.8%) 1 (1.9%) NS
Noncardiac 1 1 0
Cardiac 5 4 1
VF/arrhythmia 1 1
Sudden death 1 0
CHF 2 0
Total mortality 10 (10.8%) 8 (20.5%) 2 (3.8%) p , 0.02
CABG 5 coronary artery bypass graft; CHF 5 congestive heart failure; LMCA 5 left main coronary artery; MI 5 myocardial
infarction; PTCA 5 percutaneous transluminal coronary angioplasty; VF 5 ventricular fibrillation.
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mortality was significantly higher in group I (20.5%) com-
pared to group II (3.8%) (p , 0.02).
Correlates of Cardiac Mortality
Univariate predictors of cardiac death are listed in Table 5.
Only the final stent MLD or post-stent diameter stenoses
were predictive of mortality. Lower LVEF and the presence
of three-vessel coronary artery disease were more common
in patients who developed cardiac death; however, these
trends were not statistically significant.
DISCUSSION
Balloon Angioplasty for Unprotected LMCA Disease
Several studies have reported the results of balloon angio-
plasty (without stenting) of unprotected LMCA stenosis,
with generally poor long-term prognosis.
O’Keefe et al. (13) reported the results of 127 LMCA
balloon angioplasty procedures of which 33 were elective for
unprotected LMCA stenosis and 9 were unprotected
LMCA acute occlusions. In the elective subgroup the
procedural mortality rate was 9.1% and late mortality
reached 65% at a mean follow-up of 20 months. Repeat
revascularization procedures (PTCA or CABG) were re-
quired in 42% of patients. In nine patients who had
presented with acute occlusion, five died in-hospital; of the
four who survived to discharge, two subsequently died and
two others underwent bypass surgery.
Stenting of Unprotected LMCA Stenosis
Elective stenting of unprotected LMCA stenosis should
theoretically provide the following advantages over balloon
angioplasty alone: reduction of the risk of abrupt closure
after balloon angioplasty, greater acute gain after the pro-
cedure with a larger MLD, and a lower restenosis rate at
follow-up. The risk of subacute thrombosis after stent
placement is estimated at about 1% with the current
technique of stent implantation utilizing high pressure
and/or intravascular ultrasound guidance, together with the
use of combined aspirin and ticlopidine therapy. Both the
high concentration of elastic fibers in the aorto-ostial and
proximal segment of LMCA and subsequent marked elastic
recoil have been proposed as possible causes of the high
restenosis rates seen after conventional balloon angioplasty.
In this situation, stent implantation should result in signif-
icant reduction in restenosis.
In a recent study of LMCA stenting in a population of 42
consecutive patients with unprotected LMCA stenosis and
normal left ventricular (LV) function, Park et al. (28)
presented excellent results with a procedural success rate of
100%, clinical recurrence at six-month follow-up of 17%,
and angiographic restenosis of 22%. Only one patient died
in that series, two days after elective bypass surgery for
treatment of in-stent restenosis. That report describes a
series of patients with low surgical risk. In our series, results
in the subgroup of patients with “relatively” low surgical risk
appear satisfactory, with one death from ventricular arrhyth-
mia (3.6%). There were no other procedural or in-hospital
complications. During follow-up, three patients required
target lesion revascularization—two treated with repeat
LMCA angioplasty and one with CABG surgery.
The current results are consistent with the series reported
by Silvestri et al. (29) regarding the one-month mortality of
a group of patients considered as good candidates for
CABG (0 deaths out of 93 patients) compared with those
considered poor candidates (4 deaths out of 47 patients).
Ellis et al. (30) reported the results of a multicenter
registry of percutaneous treatment of unprotected LMCA
stenosis in 107 patients from 25 centers. Ninety-one pa-
tients were treated electively and 16 patients were treated for
MI. In the group of patients with acute MI, technical
success was achieved in 75%, and survival to hospital
discharge was 31%. In elective patients, technical success
was achieved in 98.9%. The in-hospital mortality rate was
5.9% in patients considered good candidates for CABG and
30.4% in patients not candidates for CABG. In-hospital
mortality was strongly correlated with LVEF (p 5 0.003).
Patients who had elective stenting and who were considered
as good potential candidates for CABG had an in-hospital
survival of 98% and a nine-month event-free survival of
86 6 5% when LVEF was .40%, compared with 67% and
22 6 12%, respectively, when LVEF was ,40%. Long-
term freedom from death, MI or CABG was strongly
correlated with LVEF (p , 0.001) and was inversely
related to presentation with progressive or rest angina (p ,
0.001).
In our study, the small number of end points limited our
ability to draw any statistically significant conclusions;
however, the eight patients with cardiac death had a smaller
final stent MLD than survivors, and they tended to have
lower EF and a higher prevalence of three-vessel coronary
disease.
Table 5. Univariate Analysis of the Predictors of Cardiac Death
Predictors
Cardiac
Death
(n 5 8)
Others
(n 5 84)
p
Value
Age (yrs) 75 6 4 74 6 8 NS
Male gender (%) 63 82 NS
Unstable angina (%) 88 68 NS
LVEF (%) 50 6 14 58 6 15 , 0.1
Three-vessel disease (%) 100 71 , 0.1
RCA stenosis (%) 75 39 NS
Reference vessel diameter (mm) 3.7 6 0.6 3.8 6 0.6 NS
Mean LMCA stenosis (%) 77 6 11 72 6 13 NS
Bifurcation stenosis (%) 13 6 NS
Post-stent stenosis (%) 3.7 (0–20) 1.3 (0–10) , 0.05
Final stent diameter (mm) 3.5 6 0.2 3.9 6 0.5 ,0.03
PTCA/other vessel (%) 88 63 NS
LMCA 5 left main coronary artery; LVEF 5 left ventricular ejection fraction;
PTCA 5 percutaneous transluminal coronary angioplasty; RCA 5 right coronary
artery.
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“Debulking” Before Unprotected LMCA Stenting
In our series, plaque “debulking” by rotational atherectomy
was used in only seven cases (7.6%), and the results are not
presented separately. However, preliminary data support the
concept of debulking before stenting in a general sense
(31,32). In the context of LMCA angioplasty, the concept
of “debulking” prior to stenting could be considered in some
specific anatomical conditions—for example, using rota-
tional atherectomy when the vessel is heavily calcified, or
directional atherectomy if the lesion is eccentric or bifur-
cated.
Study Limitations
This series represents a retrospective analysis of patients
who were carefully selected to undergo percutaneous revas-
cularization for LMCA disease. These patients comprise a
heterogeneous group that includes those with absolute and
relative contraindications for bypass surgery on the one
hand, and those with relatively favorable coronary anatomy
on the other. Direct comparison with a similar population
treated surgically is not possible; however, the Parsonnet
surgical risk score provides an estimate of surgical mortality
shown to be reasonably robust (33,34). The observed
procedural mortality (6SEE) in the current series (4.3 6
2.1%) compares favorably with that predicted (6SD) by the
Parsonnet score (15 6 6.9%). Further, cardiac enzyme
measurements were not done unless there was a clinical
suspicion of postprocedural ischemia, which may have led to
a systematic underestimate of ischemic complications fol-
lowing PTCA/stenting. Nevertheless, as the patients were
closely monitored during the early postprocedural period,
we believe that any clinically important ischemic events
would have been identified.
Conclusions. Our results suggest that, in selected patients,
stenting of unprotected LMCA stenoses could be consid-
ered as a feasible alternative to CABG with an acceptable
complication rate. Patients who are candidates for CABG
appear to have a better outcome than those where CABG is
contraindicated. Cardiac mortality was associated with a
trend to more extensive coronary artery disease and lower
preprocedural LVEF. Importantly, the only significant pre-
dictor of cardiac mortality was a low final stent lumen
diameter. It remains to be demonstrated that lesion “de-
bulking” by atherectomy will improve results, especially in
cases of very eccentric, calcified or bifurcated lesions.
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